"V体育平台登录" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Review
. 2020 Oct;76(4):370-376.
doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.

Favipiravir: A new and emerging antiviral option in COVID-19 (VSports在线直播)

Affiliations
Review

"VSports app下载" Favipiravir: A new and emerging antiviral option in COVID-19

Umang Agrawal et al. Med J Armed Forces India. 2020 Oct.

Abstract (V体育2025版)

With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world VSports手机版. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. .

Keywords: Antiviral drugs; COVID-19; Favipiravir; SARS-CoV-2 V体育安卓版. .

PubMed Disclaimer

Conflict of interest statement

The authors have none to declare.

Figures

Fig. 1
Fig. 1
Chemical structure of favipiravir.
Fig. 2
Fig. 2
Mechanism of action of favipiravir.
Fig. 3
Fig. 3
Figure depicting adverse effects of favipiravir (source: Fabiflu monograph).

"VSports在线直播" References

    1. Search of: favipiravir | Covid19 - list results - clinicaltrials.Gov. 2020. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=favipiravir&cnt... Clinicaltrials.gov. [online] Available at:
    1. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013 Nov;100:446–454. - "V体育安卓版" PMC - PubMed
    1. Toyama Chemicals. Summary of Product Characteristics of Avigan.
    1. Madelain V., Nguyen T.H., Olivo A. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016 Aug;55:907–923. doi: 10.1007/s40262-015-0364-1. - "VSports在线直播" DOI - PMC - PubMed
    1. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PloS One. 2013;8 - PMC - PubMed

"V体育官网入口" Publication types